enGene Therapeutics Inc.: Form 10-Q for the period ended Jul 31, 2024
Filed with the SEC on Sep 10, 2024 and accepted by EDGAR at Sep 10, 2024, 16:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-05-01 to 2024-07-31 | $11.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-11-01 to 2024-07-31 | $27.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-05-01 to 2024-07-31 | −$16.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-11-01 to 2024-07-31 | −$44.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-05-01 to 2024-07-31 | $751.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2023-11-01 to 2024-07-31 | $2.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-05-01 to 2024-07-31 | −$29.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-11-01 to 2024-07-31 | −$38.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-05-01 to 2024-07-31 | −$14.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-11-01 to 2024-07-31 | −$39.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-05-01 to 2024-07-31 | $0.32 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-11-01 to 2024-07-31 | $1.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-05-01 to 2024-07-31 | $0.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-11-01 to 2024-07-31 | $1.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-05-01 to 2024-07-31 | 44,168,986 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-11-01 to 2024-07-31 | 35,564,767 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-11-01 to 2024-07-31 | −$28.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-11-01 to 2024-07-31 | $687.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-07-31 | $257.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-07-31 | $262.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-07-31 | $266.9m | us-gaap:Assets |
| Current liabilities | At period end2024-07-31 | $13.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-07-31 | $36.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-07-31 | $230.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-105180. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.